منابع مشابه
Phosphodiesterase Inhibitors as Immunomodulatory Drugs
Los niveles intracelulares de nucleótidos cíclicos (cAMP, cGMP) tienen un papel esencial en la regulación de múltiples funciones de las células inmunes. Las fosfodiesterasas (FDEs) son un grupo grande de enzimas que ejercen un papel muy importante en la regulación de los niveles intracelulares de nucleótidos cíclicos. La pentoxifilina es un inhibidor no específico de FDE que tiene diferentes ef...
متن کاملNEW DRUGS NEW DRUGS Efalizumab for Plaque Psoriasis
NEW DRUGS Efalizumab for Plaque Psoriasis Genentech, Inc., and Xoma, Ltd., have announced the approval of efalizumab (RaptivaTM) by the U.S. Food and Drug Administration (FDA) for the treatment of chronic, moderate-to-severe plaque psoriasis in adults age 18 or older who are candidates for systemic therapy or phototherapy. This is the first biological agent that is designed to provide continuou...
متن کاملImmunomodulatory effects of anti-estrogenic drugs.
There are substantial experimental, epidemiological and clinical evidences that show that breast cancer pathology is influenced by endogenous estrogens. This knowledge is the foundation upon which endocrine deprivation therapy has been developed as a major modality for the management of breast cancer. Tamoxifen, which functions as a competitive partial agonist-inhibitor of estrogen at its recep...
متن کاملImmunomodulatory drugs: Oral and systemic adverse effects
OBJECTIVE The main objectives are to present the different adverse effects of the immunomodulatory drugs that can impair the quality of life of the immunosuppressed patients and study the impact of immunomodulation on oral diseases. Immunomodulatory drugs have changed the treatment protocols of many diseases where immune functions play a central role, such as rheumatic diseases. Their effect on...
متن کاملImmunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia.
BACKGROUND The last decade witnessed the emergence of several therapeutic options for patients with chronic lymphocytic leukemia (CLL) for first-line and relapsed settings. The vast majority of patients with relapsed or refractory CLL carry poor prognostic features, which are strong predictors of shorter overall survival and resistance to first-line treatment, particularly fludarabine-based reg...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 2003
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.327.7416.634